A Phase I Study Evaluating Escalating Doses of 90Y-BC8-DOTA (Anti-CD45) Antibody Followed by Autologous Stem Cell Transplantation for Relapsed or Refractory Lymphoid Malignancies
Latest Information Update: 18 Sep 2021
At a glance
- Drugs 90Y BC8 (Primary) ; Autologous stem cell therapy
- Indications B-cell lymphoma; Hodgkin's disease; T-cell lymphoma
- Focus Adverse reactions
- 02 Apr 2021 Biomarkers information updated
- 01 Dec 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 13 Sep 2012 New trial record